ABSTRACT
Since viruses depend on cellular enzymes for their synthesis, they are less amenable than more complex organisms to selective inhibition. However, our knowledge of viral-specific intracellular events has increased and the feasibility of viral chemotherapy has become more firmly established at least in selected situations. For example, idoxuridine, methisazone, and amantadine represent three separate chemical classes of agents generally considered to be efficacious in the treatment of viral infections in man. The use of idoxuridine against herpes keratitis in man is weil established; its clinical utility for dermal herpetic infections is less clear. Other unnatural nucleosides such as Ara-C and Ara-A also exhibit antiviral activity in various experimental infections. Methisazone has been used to prevent smallpox and alastrim in clinical contacts; it has also been used with apparent success in the treatment of vaccinia gangrenosa and eczema vaccinatum. Other thiosemicarbazones also possess similar intrinsic antiviral activity. Amantadine inhibits certain strains of influenza. Prophylaxis has been achieved in challenge sturlies and field trials against influenza A2. From more limited sturlies it also appears that this compound can be used therapeutically, that is, against already established infections. Other cyclic amines with activity against influenza are under study (e.g. rimantadine and cyclooctylamine). Relatively few additional chemical antiviral agents that hold promise for clinical utility are known at this time. However, there is considerable interest in the potential use of human interferon and interferon inducers. Humaninterferon is active in model infections, and it tlas been reported to be efficacious against influenza in man. Currently, there are serious technical impediments to its economic production. These problems may be circumvented by the use of inducers, but as yet no compound with the required combination ofproperties has been found. A few preparations have demonstrated high potency in selected model infections, but they appear too toxic for parenteral use in man. The recent observation that an orally active low molecular weight compound (tilorone) possesses interferon inducing activity may pave the way for further advances in this area.
Past experiences in viral chemotherapy and an increasing knowledge of the mechanisms of viral infections should better enable us to chart a more productive future course. The processes of compound selection, choice of screening strategy, and market goals can now be better directed. Also, contrary to past predictions, the possibility of therapy as opposed to prophylaxis appears more likely. The present status of viral chemotherapy may be likened to that of the early sulphonamide era in bacteriology. Clinically active compounds are available and the probability of finding more effective agents is very high.
1. INTRODUCTION
A review of viral chemotherapy in a symposium devoted predominant]y to antibacterials will illustrate the striking cantrast between the progress achieved in these allied areas. This is no chance event. Whereas most microorganisms have evolved into separate entities having novel structural fea tures and biochemical processes permitting independent existence, viruses areobligate intracellular parasites, largely dependent on the cellular enzymes of the host for their synthesis. Thus, far fewer opportunities are generally available for selective inhibition. Also, this intimate virus-host relationship has precluded development of comparably simple in vitro procedures for compound screening and evaluation.
Despite these considerations, the feasibility of viral chemotherapy has been firmly established. We are increasingly aware ofviral-specific events and enzymes that are theoretically amenable to selective inhibition. From a more practical standpoint, there are now several drugs that have utility in treating viral infections in man. Other compounds have been shown to possess activity in different model infections, but for various reasons these have failed to materialize as products. Further advances will undoubtedly be made, but the potential for viral chemotherapy is shrouded in a controversy based, in no small measure, on projections from past experience, dogma, and a still rudimentary knowledge of the pathogenesis of viral disease.
I shall review the current status of viral chemotherapy, but perhaps more importantly, I shall attempt to clarify some of the basic issues pertinent to an appraisal of future progress in this area. The scope of this discussion will be limited to antiviral compounds, that is, those chemotherapeutic agents whose activity depends on an inhibition of viral replication. I will not attempt a comprehensive review, but instead emphasize topics of personal interest and data from our own laboratory. No consideration will be given to the pharmacological, or symptomatic, approach. Likewise, the control of viral disease by immunologic means is a separate topic. The prophylactic value of selected vaccines is weil recognized, and the prophylactic use of immunoglobulins may also be beneficial in certain situations.
ANTIVIRAL AGENTS OF CLINICAL INTEREST
There are currently three classes of antiviral agents with at least one representative of each which is generally considered tobe efficacious in man. These three classes are the unnatural nucleosides such as idoxuridine, the thiosemicarbazones, exemplified by methisazone, and the cyclic amines of which amantadine hydrochloride is the most widely studied.
A. Unnatural nucleosides 1. Idoxuridine
This halogenated deoxynucleoside is an analogue of thymidine ( Figure 1 ). While it was originally studied in conjunction with cancer chemotherapy, its antiviral activity against herpes simplex was tirst demonstrated in vitro in an industrial screening programme in which a variety of antimetabolites were examined 1 . lts ability to inhibit other DNA viruses, including herpes zoster, is shown in Figure 2 . In this test 50 )lg of the compound on a filter 526 paper disc produces a zone where marked Inhibition of plaque development is evident; an infected but untreated control plate is shown for comparison. Lower concentrations (to 0.5 f.lg) are also effective; zone size decreases in proportioll to the amount added. Various DNA viruses are also inhibited 
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by idoxuridine in model animal infections, for example, development of adeno 12 tumours in hamsters 2 , vaccinia 3 and herpes keratitis 4 in rabbits. and herpes dermatitis in both rabbits 5 and guinea-pigs 6 • Two RNA viruses. Columbia SK and Raus sarcoma, arealso sensitive to inhibition in mice and cell culture, respectively 7 • 8 : in these instances compound action may be indirect. The observation of activity against herpes simplex in cell culture provided the impetus for Kautman to test the compound topically in rabbits against herpes keratitis 4 . Idoxuridine was clearly able to obliterate corneal disease promptly in a majority of animals. A pictorial record of such treatment is illustrated in Figure 3 . Plate 1 shows the lesion two days after virus innoculation. A fluorescein-methylene blue solutionwas used for staining. Treatment ö .... was initiated at this time; one drop of a 0.1 per cent ophthalmic solution of idoxuridine was added six times daily over a 12-hour period on consecutive days. Plate 2 shows the results two days later. 1t is evident that the treated lesion is much smaller than the control. Following three days of treatment, the eye appears normal as shown in Plate 3. In control animals, lesions usually regressed gradually after 7-8 days, often with residual scarring. In man, as in animals, Kaufman ·demonstrated that idoxuridine is an ei'fective therapeutic agent for dendritic keratitis with or without superficial stromal lesions 9 • His conclusions are borne out in a compilation of data (Table 1) summarizing some early experience with Stoxil®, a drug product containing idoxuridine. Out of 1760 cases, 1490, or 85 per cent, responded favourably; the drug was equally effective against primary and recurrent disease. Stroma] disease, on the other hand, was relatively refractory. Partial success has been achieved by combination therapy with Stoxil<a and corticosteroids. Alone, steroid application frequently Ieads to extensive spread of the infection, but in the presence ofidoxuridine the infection may be contained, so that the beneficial effects ofthe steroid on stromal healing can be obtained. Idoxuridine therapy is now well-established for the treatment of herpes keratitis, the most severe corneal infection in the United States and Europe.
There are approximately 100000 cases per year in the US and they are responsible for the majority of corneal transplants that are required. 528 The success oftreating herpes dermatitis with idoxuridine has been variable. Activity has been demonstrated in rabbits 5 and guinea-pigs 6 with systemic treatment. In addition, topical applications of a nine per cent solution of idoxuridine in 90 per cent dimethyl sulphoxide (DMSO) promoted healing of guinea-pig lesions 5 • Lower concentrations in other formulations failed to influence lesions in the rabbit 11 . Presumably, the greater concentration and better penetration achieved when DMSO was used as a solvent was decisive for activity. Clinical results appear to retlect the experience in animals. Data obtained in clinical impression studies using a 0.5 per cent dermatological ointment showed 63 per cent efficacy 10 . However, these results were not confirmed in double-blind studies. On the other band, higher concentrations of idoxuridine in DMSO have provided clinical activity against both herpes dermatitis 12 • 13 and herpes zoster 14 . The application of these findings to clinical practice remains questionable.
It was originally thought that the toxicity of idoxuridine precluded its systemic application. Although contraindicated for mild or self-limiting disease, an increasing compilation of data suggests its possible utility against herpes simplex encephalitis 15 . lt is still an investigational drug when used for this purpose, and its use is indicated only in a diagnosed herpetic infection early after onset of the infection.
Considerable information is available on the action mechanism of idoxuridine. lts functions relate to its similarity to thymidine; the only difference between the two compounds being at the 5-position of the pyrimidine ring where iodine is substituted for a methyl group. A composite representation of mechanisms by which the compound may inhibit synthesis of viral or 
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cellular DNA is shown in Figure 4 . Following phosphorylation by thymidine kinase which enables it to enter the cell, idoxuridine competitively inhibits the utilization of thymidine. Several different sites of inhibition have been proposed. Idoxuridine may inhibit not only the kinases responsible for phosphorylation of thymidine and thymidylic acid, but also polymerases which catalyse the incorporation of thymidine triphosphate into DNA. In addition, idoxuridine is incorporated into DNA to some extent. The relative sensitivity of different enzymes to inhibition varies with the system 16 . The apparent selective antiviral effect of idoxuridine probably has several explanations. Under conditions of maintenance in cell culture, it is obvious that viral synthesis may be blocked with little detrimental effect to the cells. Similarly, Iack of corneal toxicity with idoxuridine therapy may result from the normallow rate of mitosis in this tissue. On the other hand, normal comeal repair in the presence of idoxuridine is difficult to explain on this basis. However, other mechanisms may be operative. For example, studies in cell culture show that herpes simplex infection induces thymidine kinase activity 17 . As a result, a greater amount of idoxuridine is taken up and incorporated into the DNA of infected cells than in normal tissue.
Other unnatural nucleosides
Other unnatural nucleosides have also shown act1v1ty against herpes keratitis. Cytosine arabinoside (Ara-C) is active bothin rabbits and man 18 • 19 but corneal toxicity contraindicates its clinical use 20 . 5-Bromodeoxyuridine 20 ,
5-methylaminodeoxyuridine 21 and 5-trifluoromethyldeoxyuridine 22 have exhibited similar activity in rabbits. None has been considered to have sufticient clinical advantage over idoxuridine to merit product development. Tritluoromethyldeoxyuridine is more potent but its synthesis is difficult. Ara-A (adenine arabinoside) is of more recent interest. Active in vitro against a broad spectrum of DNA viruses 23 • 24 , it has also been reported to have appreciable oral activity against herpes simplex encephalitis in hamsters 25 and mice 26 , and against mouse vaccinia encephalitis 27 . Its oral therapeutic index in hamsters is superior to idoxuridine 25 .
B. Thiosemicarbazones 1. M ethisazone
The antiviral properties of a thiosemicarbazone (p-amino benzaldehyde 3-thiosemicarbazone) were tirst demonstrated by Hamre in 1950 using a vaccinia infection in eggs and neurovaccinia in mice 28 Subsequently, a wide range ofviruses were found tobe sensitive in vitro 31 -33 , but animal activity has been limited to the poxvirus group: alastrim 34 , rabbit pox 35 and smallpox 36 . Remarkably good protection has been obtained in many instances as exemplified in Figure 6 . In this instance the compound was administered orally, once a day, commencing 24 hours after infecting mice with vaccinia. Tail lesions resulting from infection were signiticant]y reduced in treated animals over a wide dose range.
In the clinic, Bauerand others have demonstrated efficacy with methisazone in the prophylaxis of smallpox by administering the compound to large numbers of contacts 37 • 38 . A similar prophylactic trial against alastrim provided similar indications of activity 39 . A compilation of these data is presented in Table 2 . The compound was effective in smallpox contacts Vomiting has been observed in a high proportion of patients. Administration of methisazone may be advisable in selected situations where rapid prophylaxis is required, but certainly mass vaccination is a more reasonable measure for smallpox and alastrim control.
No therapeutic activity against smallpox has been demonstrated, although few trials have been reported. On the other band, therapeutic activity has been reported for eczema vaccinatum and vaccinia gangrenosa 38 • 40 -45 . 531 45 These data are summarizerl in Table 3 . Since eczema vaccinatum, particularly, runs a variable course and the numbers of patients in the sturlies are small, the suggested benefit of treatment must be viewed with caution, but is promising nonetheless.
Action mechanism sturlies have been largely restricted to the effect of isatin-3-thiosemicarbazone (IBT) on vaccinia or rabbitpox. IBT inhibits neither vaccinia DNA nor mRNA synthesis 46 • 47 . Protein synthesis isselectively blockerl, but only after progeny genomes appear~~.-+Y. lt is interred that the function of mRNA required for synthesis of late proteins which package the DNA core is affected. Replication ofrabbitpox DNA is similarly unaffected whereas selected viral antigens formed late in the growth cycle fail to appear 50 . Thus, a similar inhibitory mechanism is indicated. Presumably methisazone has a similar effect against pox viruses but whether unrelaterl viruses, i.e. rhinoviruses 31 , are sensitive for the same reason is unknown.
Other thiosemicarbazones
In addition to methisazone, a number of other close analogues were founrl active against neurovaccinia in mice 29 • 30 • None has been tested in man. Although the N-ethyl analogue was somewhat more active in mice than methisazone, the latter was selected for clinical use due to greater ease of synthesis.
A more distantly related thiosemicarbazone, designated as May anrl Baker 7714 ( Figure 7) and also effective against pox viruses in animals, has been evaluated in man against smallpox in a manner similar to that of methisazone 51 . Protection was observed, but to a lesser degree than with methisazone. The incirlence of smallpox was 33 per cent in a control group of 147 persons whereas in a treaterl group of the same size, the incidence was 18 per cent. A similar proportion of deaths among smallpox patients was observed in each group. In a later therapeutic study there was no evidence of 532 activity 52 . Again, this ctrug was not well-toleratect, with vomiting the major sicte efTect. no activity was observed in ferrets but influenza A/PR8 was used as the virus inoculum in this stucty 62 . A nurober of prophylactic stucties with amantactine have now been carriect out in humans against influenza A2 either inchallenge situations 63 -67 or in 533 natural settings 68 -74 . With the exception of one challenge study 65 amantadine apparently reduced the incidence and/or severity of infection as judged by Iabaratory and/or clinical criteria. The utility of amantadine for prophylaxis of influenza was questioned 75 on the basis of data generated in the initial series of studies, principally because there was insufficient demonstration of clinical effect in the field. Later investigations, using 4559 treated subjects in Leningrad during an influenza A2/Hong Kong epidemic in 1969, reinforced the initial contention that the compound was active. In this study The results of these studies are summarized in Table 5 . All studies suggest benefit from sfrug treatment. Virus isolates varied but in most studies were A2/Hong Kong serotypes. In most instances the drug was first administered during the initial 48 hour period of fever, but data on some patients with a Ionger duration of fever are also included. Generally a significant reduction in duration of fever was obtained, particularly in those patients who were treated early. Also, subjective clinical signs and symptoms were reduced in duration and/or severity. Quantitative values to express these effects were generally not amenable to this type of tabulation. If the results of these studies are substantiated by 534 much further investigation, the use of amantadine against flu-like illness may be merited during epidemics of influenza A2.
C. Cyclic amines
Immunization is still the first line of defence against influenza. Nonetheless, amantadine may be a useful adjunct, particularly in high-risk groups, during proven influenza A2 epidemics. Whether succeeding strains of influenza will share the in vivo sensitivity of A2 viruses or be refractory, as is A/PR8, can only be speculated.
Action mechanism studies with influenza Astrains reveal that amantadine inhibits the penetration of the virus into the ce11 82 • Other studies employing fowl plague virus show that the virion penetrates the cell, but that the subsequent uncoating of viral nucleic acid is inhibited 56 . Since the nature of the penetration step with influenzaisnot known, the two results may be compatible.
Other cyclic amines
Approximately 50 additional mono-, bi-and tri-cyclic amines of varying structure have been found active against influenza A2 mouse infections in our laboratory 83 . One of the simpler, more active, and best tolerated of these is cyclooctylamine (Figure 10) 84 . Oral dosing of mice provides activity comparable to that of amantadine. In addition, intranasal administration is ONH,·HCI highly effe_ctive as shown by exposing mice infected with influenza A2 to aerosols ofthe compound at multiple times over a three day period (Figure 11 ). The compound is similarly effective when administered by drop instillation.
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In addition, cyclooctylamine can inhibit natural spread of influenza among ferrets 85 . This compound is currently under clinical evaluation in man. Stillother cyclic amines have been reported to have antiviral activity. For example, N-methyl-adamantane-2-spiro-3'-pyrrolidine has been studied extensively in the laboratory and is considered to have a slightly better therapeutic index than the parent compound 86 . Rimantadine hydrochloride (Figure 12 ) has also shown good in vitro and in vivo activity against infection by influenza A viruses 87 • 88 . In human volunteers, a prophylactic effect equivalent tothat of amantadine was observed in one challenge study 89 and therapeutic value, again comparable tothat of amantadine, has been indicated in two studies with natural infection 80 • 90 .
INTERFERON AND INTERFERON INDUCERS
A review of viral chemotherapy would be incomplete without considering 536 the potential clinical use of exogenaus interferon or interferon inducers. Although interferon was described in 1957 91 and, in retrospect noninfectious interferon inducers were available since the discovery of statalon 92 in 1952 and helenine 93 in 1953, few clinical studies with such materials have been reported to date. A ]arge volume of laboratory data has appeared, however, which reflects the great interest in this area, and has been the subject of recent comprehensive reviews 94 • 95 . Interferons are low molecular weight proteins synthesized by cells in response to viral and other microbial infections, as well as to certain viral nucleic acids and non-viral substances. Their in vitro activity extends to virtually all viruses, but has considerable quantitative differences in sensitivity. In animal infections their antiviral spectrum is more limited, presumably because of differences in viral sensitivity and disease pathogenesis, but the range of antiviral protection, particularly with inducers, is impressive. In addition, interferons are essentially non-toxic and non-antigenic in the homologaus host. Consequently, they are of great practical interest.
Impediments to the use of exogenaus interferon relate primarily to production. In addition, interferons are not orally active and human interferon has been considered unstable when concentrated. Since interferons are, to a large extent, species specific, interferon for human use must be obtained from either monkey or human cells. Cultured cells vary widely in their capacity to produce this material by present methods of manipulation. Production in human leukocytes (buffy coats obtained from blood banks) is currently the most practical method 96 • 97 . Even here, yields are low and new technology is needed before interferon can be produced economically for wide usage.
Limited studies indicate that human interferon is efficacious in sub-human primates. Used intravenously, it has been effective against vaccinia 98 in baboons, and vaccinia 99 and yellow fever 100 in monkeys. It is also effective intradermally against monkey vaccinia dermatitis 100 . The following study illustrates the effects that can be obtained (Table 6 ). Vaccinia was titrated intradermally on the backs of rhesus monkeys. Human leukocyte interferon was injected intravenously at different doses by the indicated regimens. A 
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prophylactic effect was observed as indicated by a reduction in lesion titre, but there was only questionable activity when interferon was given first 24 hours after infection. The size of the remaining lesions in the prophylactic trialwas also reduced as shown in Figure 13 . In man, monkey interferon has been reported to prevent the vaccination response when injected at the vaccination site 101 , and tobe effective against vaccinia keratitis 102 when administered topically. Of greater interest, human leukocyte interferon has been reported to lower the incidence of influenza A2-associated illness when applied intranasally during two natural disease outbreaks 103 • 104 . One of these studies, performed by Solov'ev, involved 5374 treated volunteers; approximately 60 per cent less disease was observed in this group than in a similar group of controls. In neither study was influenza confirmed by laboratory diagnosis. More important, there was no indication that controls were given a comparable preparation lacking interferon or that the interferonwas examined for its Ievel of influenza antibodies and nonspecific viral inhibitors. The latter are commonly present in high titres in interferon concentrates, since human serum is usually used in the leukocyte incubation medium. The intranasal administration of gamma-globulin (i.e. antibodies) has been shown tobe similarly effective for the prophylaxis of an upper respiratory tract viral infection 105 . Therefore, beneficial results when obtained cannot be clearly attributed to the interferon content of the material. Other interferon trials 96 • 106 in man have been limited in scope and tentative in conclusions. Further well-controlled studies are required to evaluate this chemotherapeutic approach.
An alternate and, possibly, more attractive approach to interferon therapy is the use of non-infectious agents which induce the body to synthesize its own interferon. A number of such substances are now known (Table 7) . Many other such compounds have been shown to induce interferon either in vitro or in vivo, and to provide in vitro antiviral protection, but their ability to protect animals against infection either has not been examined or reported. The conclusion that the observed in vivo activity is a consequence of interferon induction is somewhat tenuous. Circulating interferon is frequently not dernonstrahle at protective doses, or protection may extend far beyond the time that interferon Ievels are observed. However, the association between 539 these two events is borne out by several indirect lines of evidence. Since small quantities of interferon· can produce antiviral activity, it is reasoned that Ievels present and persisting in target tissues are too low tobe detectable by present assay methods. The antiviral potency of an interferon inducer against comparable infections in ditTerent hosts correlated directly with its ability 
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to induce interferon in these species 127 . Poly (I: C) induces high titres of interferon in the rabbit following intravenous administration of 2 ~g per animal 118 , but none could be detected in the rhesus monkey after similar administration of 3 mg per animal 127 . Protection studies with Poly (I: C) against vaccinia dermatitis in rabbits and rhesus monkeys are illustrated in . Figure 14 . The compound was administered intravenously 24 hours before infection. Although activity was dernonstrahle in both species, potency in the rabbit is significantly greater. Also, the inducers have a broad spectrum of antiviral activity reminiscent of interferon, provide a degree of protection in vivo which at least roughly correlates with the sensitivity of the virus to interferon in vitro, and exhibit a time lag to optimal effect; this is consistent with the fact that interferon is not detected in high titre in cultured cells for several hours afterincubation with inducer, and antiviral activity is not optimally established until after that time. The relationship between time of Poly (I: C) administration and activity is illustrated for a mengovirus infection in mice in Figure ] 5 8 3 . The compound was administered intraperitoneally in a single dose of 1.3 mg/kg against an LD 90 infection. Optimal activity was obtained when the compound was given 18 hours before infection, but activity diminished gradually with earlier dosing and rapidly, approaching the time of infection. Repeated dosing can sustain an antiviral effect. Duration of protection varies widely with the inducer. For example, polyacrylic acid can provide activity for at least eight weeks after administration 125 . Also, activity can be achieved against certain infections when inducers are administered after the time of virus inoculation. For example, Poly (I: C) provides significant protection against Semliki Forest 128 and vaccinia 129 viruses in mice when administered as late as five days after infection.
The in vivo profile of these inducers varies widely with respect to potency, therapeutic index, and extent of testing. The plastics have a relatively low order of activity. Serious side effects including fever and haematologic disorders Iimit the use of pyran copolymer at etfective Ievels in man 130 . Poly (I: C) likewise produces a spectrum oftoxic efTects in several species following parenteral administration at low doses 131 . It appears, however, that a favourable activity: toxicity ratio may be attainable by intranasal administration in man against selected viruses producing respiratory disease 131 . Other inducers, notably carbohydrates and double-stranded RNAs from natural sources, have not been adequately evaluated in this respect.
Aside from questions oftoxicity the use ofthe polymeric inducers is limited by their lack of oral activity: parenteral administration is indicated for systemic disease, and intranasal, for respiratory tract infections. Therefore, tilorone hydrochloride, which is active orally, parenterally and intranasally against a variety of Iabaratory infections, has attracted recent attention (Figure 16 ). This compound has a simple structure and represents a new dass of interferon inducers. lt is the only small molecular weight inducer and the only one ofknown structure. Unfortunately, potency is low and it remains for other compounds ofthisnature to be discovered.
Reported clinical studies have been limited to the use of Poly (I: C) 132 .
In very small numbers of volunteers, intranasal administration of the compound provided suggestive evidence of protection against a rhinovirus and an influenza A2 challenge. However, no conclusions can yet be drawn on its clinical efficacy.
OTHER ANTIVIRAL COMPOUNDS
A vast assortment of additional compounds have been reported to have in vitro antiviral activity. Some of these have proven to be useful in the study of biosynthetic pathways, but most are of no practical interest. Far fewer, but still substantial numbers, have convincing activity in animal infections. field trial against influenza A2 and adenovirus infection 142 . The conflicting experiences and lack of profound activity in positive studies have negated wide interest in this compound.
ISSDES PERTINENT TO FUTURE PROGRESS
Through a great deal of effort, it has been shown that viral chemotherapy is feasible. The experience gained in this endeavour should better enable us to chart a future course and predict the outcome.
A. Screening strategy
The activity of all three clinically useful antiviral classes of compounds was first discovered by a more or less random screening process. However, the compound in question, or its prototype, had other known biological activity; thiosemicarbazones as antituberculars, octachloroadamantane as an insecticide, and idoxuridine per se as a recognized metabolic inhibitor. Random screening yields relatively few compounds of interest (Table 8 obtained a Iead, the incidence of activity among analogues synthesized araund this structure may be much greater. For example, 133 cyclic amines ofvarying structure were synthesized in this Iabaratory as a consequence of interest in cyclooctylamine. Fifty or 38 per cent were active in mice against influenza A2. The nurober of other active thiosemicarbazone analogues and substituted nucleosidesappearing after the initialleadwas obtained, attest to the success of similar analoguing programmes. Thus, it would appear that high volume random screening, the testing of all available compounds with known biological activity, and vigoraus analoguing programmes araund Ieads may provide additional payoff. Most antivirals of special interest today are synthetic. Many from a variety of natural sources, however, show in vitro activity, and several are active in animals. Problems in production, fractionation, and purification of such materials impede their evaluation but, as with antibacterials, natural products may ultimately be a rich source of antivirals.
B. Screening methods
The basic choices in screening methodology are between in vitro or in vivo models, and the selection of viruses. Compounds can be tested more efficiently agairrst a greater variety of viruses in vitro. Possibly the plaque inhibition test is the system of choice. On the other hand, interest depends largely on activity in vivo, so that if 'appropriate' and easily manipulated small animal infections are available, they are often preferable for testing compounds directly. By so doing, certain antivirals deserving special attention may be missed but others, metabolized to active products or possessing indirect action, may be discovered. All screens have holes. Commonly used,animal infections are often markedly dissimilar to the human target infections for Encephalitic infections are often used (i.e. herpes simplex and vaccinia) as models for predominantly non-encephalitic human diseases. Such a choice is hazardous, since many, particularly ionized compounds, fail to cross the blood-brain barrier. In general, an attempt is made to select viral strains which are closely related to those responsible for the target infections in man.
This is readily accomplished in some instances (i.e. influenza, herpes simplex and vaccinia); however, there are exceptions. Rhinoviruses are a frequent target for chemotherapy, but no small animal rhinovirus infection is available for use. Other non-respiratory picornavirus infections can be produced in mice, but they have questionable application. Antiviral activity may be selective among the picornavirus group as illustrated in Table 9 for a number of compounds with plaque inhibition activity against 4/4 rhinoviruses in vitro. Circumventing these animal models in the development of compounds with rhinovirus activity is arduous, but feasible
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. With rhinovirus interest firmly established by qualitative and quantitative in vitro techniques, metabolic studies can largely define the potential for absorption, stability, and appropriate tis$Ue distribution, concentration and retention. Furthermore, subclinical rhinovirus upper respiratory infections can be produced in chimpanzees and gibbons 145 • 146 . These systems can be used for evaluation of selected compounds with the effect measured in terms of viral isolation from nasal secretion, and by antibody response, as illustrated for an experimental compound in Figure 19 . In this example, the compound produced an apparent, but not significant, reduction in both incidence ofvirus shedding and seroconversion.
C. Market areas The cost of a directed antiviral screening effort is exceedingly great. Promising compounds must be subsequently evaluated for toxicity and then tested extensively in the clinic. Few compounds have been or will be marketed relative to input. A careful assessment of need, probable usage and feasibility must, therefore, be made for different disease areas. An ideal compound would have clear therapeutic utility agairrst a prevalent (preferably serious) disease syndrome, be essentially non-toxic, and readi1y available at low cost.
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Many diseases of known or suspected viral aetiology are candidates for a compound with such a protile. Serious problems arise short of this goal. The marketability of a therapeutic agent diminishes with disease incidence, though seriousness counterbalances this equation.
Chemoprophylaxis is attractive in the absence of an adequate vaccine provided (1) the disease has high incidence, (2) occurs in recognizable epidemics and (3) sensitive viruses are predominantly responsible. This situation potentiaily applies to influenza and the common cold. With sufficiently broad activity (i.e. influenza A and B, para-influenzas and rhinoviruses) a prophylactic agent could be useful in respiratory disease seasons in the absence of epidemics.
D. Spectrum of activity
Antiviral agents are frequently considered to have narrow spectra of activity. Several striking examples already cited are cases to point. These do not necessarily foreteil the future. however. Experimental compounds. albeit with certain liabilities. exhibit intrinsic antiviral activity against a wide (Table 10 ). Possibly other compounds willexhibitsuch a breadth of activity in vivo.
E. Therapeutic potential
Without exception, prophylaxis is more attainable with antiviral compounds than is therapy. This conclusion is based on experience as weil as on the kinetics of viral disease relative to replication of the aetiologic agent. Disease, usually measured by pathology, is frequently first observed when peak viral titres are attained. Caution must be applied in the extrapolation of such data, however: (1) the pathogenesis ofviral disease varies widely, and that ofhuman disease is rarely well-known, (2) pathology is not synonymous with symptomatology-the latter undoubtedly appears earlier, and (3) peak titres represent a balance between continued viral replication and the inactivation and removal of the agent; considerable, and possibly critical, amounts of viral material are synthesized after this time.
Diseases with a slow course of development are undoubtedly the better candidates for therapy. However, even acute conditions have been shown amenable to treatment well after initiation of viral replication as illustrated by clinical data with amantadine and idoxuridine and by the following example using hyperimmune serum against influenza A/PR8 in mice ( Figure  20 A/PR8 in mice were injected subcutaneously at the indicated times in relation to infection with an LD 90 of virus. Although activity diminished with delay in treatment, a significant protective effect was still observed when the antiserum was first applied 72 h after infection.
In conclusion, the status of viral chemotherapy may be likened tothat of the early sulphonamide era in bacteriology. Clinically active compounds are available and feasibility for more effective applications is established.
